Medicenna Therapeutics Corp. announced the appointment of Dr. Arash Yavari as the Chair of its Development Advisory Committee. Dr. Arash Yavari is a physician-scientist with over 20 years of broad clinical, scientific and industry drug development experience.

He has extensive expertise in early clinical development and scientific strategy across a range of therapeutic areas, including immuno-oncology, hemato-oncology, inflammation, autoimmunity, cardiometabolic and rare disease. Dr Yavari is a University Research Lecturer and Principal Investigator at the Radcliffe Department of Medicine, University of Oxford, CSO of Imbria Pharmaceuticals, and serves as Senior Drug Development Clinician with Weatherden, a London-based biotech-focused consulting organization. Dr. Yavari holds a BSc and MBBS from the University of London, and a DPhil from the University of Oxford.